--- title: "AstraZeneca Stock Leads 3 Cash Flow Picks Trading Below Fair Value" type: "News" locale: "en" url: "https://longbridge.com/en/news/294747294.md" description: "The article highlights three undervalued stocks based on cash flow analysis: AstraZeneca, Foresight Group Holdings, and Diaceutics. AstraZeneca trades below its DCF estimate despite a high P/E, with merger talks adding complexity. Foresight Group offers infrastructure exposure at a low P/E but faces execution risks. Diaceutics trades at a significant discount to fair value with strong growth forecasts, though it carries execution risks due to recent profitability and short board tenure." datetime: "2026-08-03T23:29:55.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294747294.md) - [en](https://longbridge.com/en/news/294747294.md) - [zh-HK](https://longbridge.com/zh-HK/news/294747294.md) --- # AstraZeneca Stock Leads 3 Cash Flow Picks Trading Below Fair Value Global data is sending a mixed but useful message for value investors. Manufacturing and trade are stabilising in several regions, inflation is cooling in others, and bond markets are adjusting to shifting rate expectations. That kind of backdrop often rewards patience and discipline. Undervalued stocks based on cash flows can give you exposure to companies where the market price does not fully reflect their underlying cash generation. The SWS DCF driven screener looks for exactly that. In this article, you will see three stocks from the Undervalued Stocks Based On Cash Flows list that stand out right now. ## AstraZeneca (LSE:AZN) **Overview:** AstraZeneca is a global biopharmaceutical company that researches, develops, manufactures, and sells prescription medicines across oncology, cardiovascular and metabolic diseases, respiratory and immunology, vaccines, and rare disease treatments. **Operations:** AstraZeneca generates about $61.4b in revenue from its pharmaceuticals segment. **Market Cap:** £195.9b AstraZeneca interests investors who want exposure to large scale pharmaceuticals that are tightly linked to cash generation. The company sits on a broad oncology and rare disease portfolio, with recent approvals such as Datroway, Etcamah and Enhertu supporting the idea that its late stage pipeline still has room to grow future cash flows. Analysts expect earnings growth and high forecast returns on equity. Yet the stock screens as trading below Simply Wall St's DCF estimate while carrying a higher P/E than many pharma peers. That gap, together with merger talks with Bristol Myers Squibb and heavy reliance on a handful of blockbuster drugs, creates a mix of opportunity and risk that is not fully explained by headline valuation alone. AstraZeneca’s cash rich pipeline and higher P/E hint that the story is not just about today’s price. The real question is what the market might be missing about its future cash generation and risk balance in the DCF valuation analysis for AstraZeneca AZN Discounted Cash Flow as at Aug 2026 ## Foresight Group Holdings (LSE:FSG) **Overview:** Foresight Group Holdings is an asset manager that runs infrastructure, private equity, venture capital, and listed funds, with a focus on renewable energy projects, social and digital infrastructure, and providing equity and credit to smaller companies across several regions. **Operations:** Foresight Group Holdings generates about £114.8m from Real Assets and £50.1m from Private Equity, with most revenue coming from the United Kingdom and a meaningful contribution from Australia. **Market Cap:** £512.6m Foresight Group Holdings catches investors’ attention because it combines exposure to long term themes like energy transition and infrastructure with solid profitability and a P/E that sits below some analyst fair value estimates. Assets under management still represent a small share of its target markets. Buybacks and growing fee income give earnings per share and dividends room to develop if conditions remain supportive. At the same time, you have to weigh execution risks such as rising costs, dependence on performance fees, and sensitivity to UK and European regulation. If you want to understand what the current share price might be missing about that balance of growth potential and risk, the rest of this analysis goes much deeper into the details. Foresight Group Holdings sits at an interesting crossroads where fee income, buybacks and exposure to long term infrastructure trends meet a P/E that some investors may be underestimating. To see what the market might be missing about that mix, go straight to the analysis report for Foresight Group Holdings FSG Discounted Cash Flow as at Aug 2026 ## Diaceutics (AIM:DXRX) **Overview:** Diaceutics is a Belfast based diagnostics commercialization company that helps pharma and biotech firms ensure the right patients are identified for precision medicines, using its DXRX data and analytics platform to connect laboratories, physicians, and treatment decisions. **Operations:** Diaceutics generates about £38.4m from its Medical Labs & Research activities, with most revenue coming from North America and smaller contributions from the UK, Europe, and Asia and the Rest of World. **Market Cap:** £121.5m Diaceutics provides exposure to precision medicine through a data rich platform that connects diagnostic testing and treatment decisions, which can help drug companies reach eligible patients faster. The stock trades at a large discount to Simply Wall St's DCF estimate and at a P/S below many peers. Analysts currently expect very strong earnings and revenue growth over the coming years. At the same time, return on equity is very low, the company only recently moved into a small profit and board tenure is short, so execution risk is present. For investors assessing whether the growth forecasts and valuation gap justify those risks, the deeper analysis on Diaceutics explains what might be missing. Diaceutics sits at the point where a data heavy platform, a low P/S, and a recent move into profit meet questions about how far growth can stretch. The analyst forecasts for Diaceutics could show what the current share price is not pricing in yet. DXRX Discounted Cash Flow as at Aug 2026 The three stocks in this article are only a starting point, and the full Undervalued Stocks Based On Cash Flows screener surfaced 40 more companies where discounted cash flow signals and real world business stories line up in interesting ways. Use Simply Wall St to identify and analyze the specific cash flow catalysts, valuation gaps and risk profiles that fit your own highest conviction ideas. ## Take Control of Your Investment Journey If Foresight Group Holdings or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market. ## Seeking Fresh Alternatives Before They Fly Fresh ideas do not stay under the radar for long. Once momentum builds, prices move and ideal entry points start dropping away. Scan these curated lists now to review opportunities at an earlier stage. - Spot resilient businesses before the crowd by running through a curated set of 8 resilient stocks with low risk scores that keep risk scores in focus while the market reacts to headlines. - Explore structural demand shifts by scanning a pre filtered group of 35 power grid technology and infrastructure stocks focused on the upgrade cycle in transmission, storage, and grid technology. - Review hard asset exposure with a focused universe of 32 elite gold producer stocks that highlight production quality and balance sheet strength. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [AZN.US](https://longbridge.com/en/quote/AZN.US.md) - [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md) - [BMY.US](https://longbridge.com/en/quote/BMY.US.md) - [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md) ## Related News & Research - [AstraZeneca in talks over £300bn mega-merger with US rival – reports](https://longbridge.com/en/news/294669830.md) - [Why Is Bristol-Myers Squibb Stock Surging Monday?](https://longbridge.com/en/news/294697898.md) - [AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus](https://longbridge.com/en/news/294722299.md) - [Keel Point LLC Sells 7,624 Shares of Astrazeneca Plc $AZN](https://longbridge.com/en/news/294671516.md) - [Key facts: AstraZeneca (AZN) merger talks with BMS; 6% revenue rise](https://longbridge.com/en/news/294654032.md)